Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
暂无分享,去创建一个
D. Faller | L. Adès | J. Liesveld | M. Sekeres | N. Tzvetkov | C. Graux | D. Selleslag | J. Watts | J. Zeidner | M. Cerrano | Dan-dan Zhao | J. Bell | M. D. Campelo | R. Fram | A. Radinoff | M. A. Sangerman | P. F. Lopez | S. Friedlander | M. Campelo
[1] A. Letai,et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.
[2] D. Faller,et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. , 2018, Blood.
[3] J. Reeves,et al. Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes , 2017, Cancer.
[4] C. Bloomfield,et al. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Gore,et al. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults , 2013, Haematologica.
[6] H. Kantarjian,et al. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. , 2011, Seminars in oncology.
[7] B. Esterni,et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Ping Li,et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. , 2010, Molecular cell.
[9] Peter G. Smith,et al. Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer , 2009, Clinical Cancer Research.
[10] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[11] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[12] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[13] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.